Solid Tumor Oncology
Turning Point Therapeutics Inc. focuses on advanced solid tumors, with clinical research centered on metastatic malignancies and genetically defined cancer populations.
- Advanced solid tumors
- Metastatic malignancies
- Genomic oncology
The sponsor’s clinical portfolio reflects a strong interest in identifying targeted treatment options for difficult-to-treat tumor types.
ROS1-Driven Cancers
Its research activity includes tumors with ROS1 rearrangements, a key molecular target in precision oncology for both adult and younger patient groups.
- ROS1 rearrangements
- Targeted cancer therapy
- Precision oncology
These studies highlight interest in molecularly selected cancers where oncogenic fusions define treatment relevance.
NTRK Fusion-Positive Malignancies
The sponsor is active in NTRK1, NTRK2, and NTRK3 rearranged tumors, supporting clinical research across multiple tumor-agnostic settings.
- NTRK gene rearrangements
- Fusion-positive solid tumors
- Tumor-agnostic oncology
This area includes both broad solid tumor cohorts and genetically selected populations defined by TRK alterations.
MET-Altered Solid Tumors
Turning Point Therapeutics Inc. also funds research in solid tumors harboring MET alterations, extending its therapeutic interest to another actionable oncogenic driver.
- MET genetic alterations
- Actionable oncogenic drivers
- Molecularly targeted treatment
This reflects involvement in cancers where biomarker-defined selection is central to clinical development.
Pediatric and Young Adult Oncology
The sponsor’s trials also include pediatric and young adult patients with advanced or metastatic cancer, indicating interest in age-specific oncology research.
- Pediatric oncology
- Young adult oncology
- Advanced or metastatic malignancies
Clinical activity in this area spans genetically altered tumors with ALK, ROS1, and NTRK alterations.
